AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Nektar Therapeutics (NASDAQ:NKTR)
59.23 USD
+0.670 1.144%Sponsored Reports
Loading...
| Previous Close (in USD) | 58.56 |
|---|---|
| Change | +0.670 1.144% |
| 52 W H/L (in USD) | 1.928/0.413 |
| EBITDA (in USD) | -125.541M |
| PE Ratio | -- |
| Volume | 892644 |
| Diluted Eps TTM | -0.91 |
| Total Assets (in USD) | 398.033M |
|---|---|
| Total Liabilities (in USD) | 267.046M |
| Revenue TTM (in USD) | 90.167M |
| Cash (in USD) | 20.161M |
| Market Cap (in USD) | 275.438 M |
| Revenue Per Share TTM | 0.471 |
| Gross Profit TTM (in USD) | 70.42M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
455 Mission Bay Boulevard South, San Francisco, CA, United States, 94158
415 482 5300
Employees: 137
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Howard W. Robin | CEO, Pres & Director | 1953 |
| 2. | Mr. Mark A. Wilson | Chief Legal Officer & Sec. | 1972 |
| 3. | Dr. Jonathan Zalevsky Ph.D. | Sr. VP & Chief R&D Officer | 1975 |
| 4. | Mr. John P. Northcott | Strategic Consulting Advisor | 1978 |
| 5. | Ms. Jillian B. Thomsen | Chief Financial Officer | 1966 |
| 6. | Mr. Robert Bacci | Sr. VP of HR & Facilities Operations | NA |
| 7. | Ms. Jennifer Ruddock | Chief Bus. Officer | NA |
| 8. | Dr. Mary Tagliaferri L.Ac., M.D. | Chief Devel. Officer | 1966 |
| 9. | Dr. Brian L. Kotzin M.D. | Chief Medical Officer | 1949 |
| 10. | Dr. Kevin Brodbeck Ph.D. | Sr. VP of Technical Operations | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.920 2.144% | 42.715 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.750 1.734% | 42.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+3.250 0.765% | 420.63 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+16.030 2.659% | 600.79 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -364.983M | -523.28M | -443.947M | -440.054M | 682.725M |
| Minority Interest | - | - | - | - | - |
| Net Income | -368.198M | -523.837M | -444.44M | -440.667M | 681.313M |
| Selling General Administrative | 92.333M | 122.844M | 104.682M | 98.712M | 81.443M |
| Gross Profit | 70.42M | 77.01M | 133.438M | 93.243M | 1168.911M |
| Reconciled Depreciation | 13.03M | 14.146M | 14.182M | 13.156M | 10.87M |
| Ebit | -240.236M | -446.103M | -379.922M | -440.035M | 725.503M |
| Ebitda | -220.539M | -453.798M | -347.458M | -380.544M | 736.373M |
| Depreciation And Amortization | 19.697M | -7.695M | 32.464M | 59.491M | 10.87M |
| Operating Income | -240.236M | -446.103M | -379.922M | -440.035M | 687.932M |
| Other Operating Expenses | 332.291M | 548.01M | 532.837M | 554.652M | 505.391M |
| Interest Expense | 28.911M | 47.313M | 37.118M | 46.354M | 42.778M |
| Tax Provision | 3.215M | 0.557M | 0.493M | 0.613M | 1.412M |
| Interest Income | 6.667M | 2.569M | 18.282M | 46.335M | 37.571M |
| Net Interest Income | -22.244M | -44.744M | -18.836M | -0.019M | -5.207M |
| Income Tax Expense | 3.215M | 0.557M | 0.493M | 0.613M | 1.412M |
| Total Revenue | 92.055M | 101.907M | 152.915M | 114.617M | 1193.323M |
| Total Operating Expenses | 310.656M | 523.113M | 513.36M | 533.278M | 480.979M |
| Cost Of Revenue | 21.635M | 24.897M | 19.477M | 21.374M | 24.412M |
| Total Other Income Expense Net | -124.747M | -77.177M | -64.025M | -0.019M | -5.207M |
| Net Income From Continuing Ops | -368.198M | -523.837M | -444.44M | -440.667M | 681.313M |
| Net Income Applicable To Common Shares | -368.198M | -523.837M | -444.44M | -440.667M | 681.313M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 398.033M | 710.6M | 1117.189M | 1538.767M | 1977.356M |
| Intangible Assets | - | - | - | - | 26.91M |
| Other Current Assets | 8.732M | 15.808M | 23.333M | 18.02M | 15.387M |
| Total Liab | 267.046M | 343.962M | 437.681M | 461.472M | 571.965M |
| Total Stockholder Equity | 130.987M | 366.638M | 679.508M | 1077.295M | 1405.391M |
| Other Current Liab | 22.162M | 36.557M | 58.012M | 79.634M | 67.933M |
| Common Stock | 0.019M | 0.019M | 0.019M | 0.018M | 0.017M |
| Capital Stock | 0.019M | 0.019M | 0.019M | 0.018M | 0.017M |
| Retained Earnings | -3477.249M | -3201.193M | -2832.995M | -2309.158M | -1864.718M |
| Good Will | 0M | 76.501M | 76.501M | 76.501M | 76.501M |
| Other Assets | - | 2.245M | 2.744M | 264.599M | 1.01M |
| Cash | 20.161M | 88.227M | 25.218M | 198.955M | 96.363M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 51.269M | 68.204M | 85.2M | 115.779M | 353.893M |
| Current Deferred Revenue | - | - | - | 0.091M | 5.517M |
| Net Debt | 210.24M | 43.269M | 117.959M | -48.667M | 307.576M |
| Short Term Debt | 19.259M | 18.667M | 17.441M | 13.915M | 261.209M |
| Short Long Term Debt | - | - | - | - | 248.693M |
| Short Long Term Debt Total | 230.401M | 131.496M | 143.177M | 150.288M | 403.939M |
| Other Stockholder Equity | 3608.137M | 3574.719M | 3516.641M | 3388.73M | 3271.097M |
| Property Plant Equipment | - | 85.886M | 177.535M | 59.662M | 64.999M |
| Total Current Assets | 330.701M | 545.968M | 795.581M | 1138.005M | 1421.55M |
| Long Term Investments | 25.825M | 0M | 64.828M | 136.662M | 279.119M |
| Short Term Investments | 283.455M | 416.75M | 708.737M | 862.941M | 1228.499M |
| Net Receivables | 2.252M | 5.981M | 22.492M | 38.889M | 36.802M |
| Long Term Debt | - | - | - | - | - |
| Inventory | 16.101M | 19.202M | 15.801M | 15.292M | 12.665M |
| Accounts Payable | 9.848M | 12.98M | 9.747M | 22.139M | 19.234M |
| Accumulated Other Comprehensive Income | 0.08M | -6.907M | -4.157M | -2.295M | -1.005M |
| Non Currrent Assets Other | 4.644M | 2.245M | 2.744M | 1.461M | 1.01M |
| Non Current Assets Total | 67.332M | 164.632M | 321.608M | 400.762M | 555.806M |
| Capital Lease Obligations | 117.776M | 131.496M | 143.177M | 150.288M | 155.246M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | 365.835M | 217.766M | 503.471M | 233.171M | -1368.33M |
| Total Cashflows From Investing Activities | 365.835M | 202.777M | 496.213M | 206.886M | -1379.936M |
| Total Cash From Financing Activities | 1.508M | 36.238M | -80.354M | 23.355M | 851.966M |
| Net Income | -368.198M | -523.837M | -444.44M | -440.667M | 681.313M |
| Change In Cash | 63.009M | -173.737M | 102.592M | -98.542M | 190.143M |
| Begin Period Cash Flow | 25.218M | 198.955M | 96.363M | 194.905M | 4.762M |
| End Period Cash Flow | 88.227M | 25.218M | 198.955M | 96.363M | 194.905M |
| Total Cash From Operating Activities | -304.007M | -412.66M | -313.287M | -328.681M | 718.214M |
| Depreciation | 13.03M | 14.146M | 14.182M | 13.156M | 10.87M |
| Other Cashflows From Investing Activities | - | - | - | 233.171M | 2.633M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | -3.401M | -0.509M | -2.627M | -1.284M | -0.655M |
| Sale Purchase Of Stock | - | 33.238M | 23.396M | 23.355M | 851.966M |
| Other Cashflows From Financing Activities | 1.508M | 36.238M | 169.646M | 23.355M | 61.735M |
| Capital Expenditures | 5.676M | 14.989M | 7.258M | 26.285M | 14.239M |
| Change In Working Capital | 0.492M | -23.076M | 16.712M | 21.688M | -39.006M |
| Other Non Cash Items | -9.359M | 17.41M | -14.353M | -22.653M | -23.064M |
| Free Cash Flow | -309.683M | -427.649M | -320.545M | -354.966M | 703.975M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 5724732 |
| 2. | PRIMECAP Odyssey Aggressive Growth | 2 years ago | 4233380 |
| 3. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 2676857 |
| 4. | PRIMECAP Odyssey Growth | 2 years ago | 2072356 |
| 5. | Vanguard Strategic Equity Inv | 2 years ago | 1517103 |
| 6. | Fidelity Extended Market Index | 2 years ago | 1061973 |
| 7. | BlackRock Advantage Small Cap Core Instl | 2 years ago | 969915 |
| 8. | Schwab US Small-Cap ETF™ | 2 years ago | 912965 |
| 9. | Vanguard Strategic Small-Cap Equity Inv | 2 years ago | 763309 |
| 10. | Vanguard Health Care ETF | 2 years ago | 640997 |
| 11. | BlackRock Extended Mkt Composite | 2 years ago | 538851 |
| 12. | Invesco FTSE RAFI US 1500 Small-Mid ETF | 2 years ago | 532085 |
| 13. | Vanguard US Opportunities Ins USD Acc | 2 years ago | 521011 |
| 14. | BlackRock Extended Equity Market K | 2 years ago | 470272 |
| 15. | Fidelity Total Market Index | 2 years ago | 331350 |
| 16. | Vanguard Market Neutral I | 2 years ago | 261128 |
| 17. | Delaware Healthcare I | 2 years ago | 256385 |
| 18. | Fidelity Series Total Market Index | 2 years ago | 247674 |
| 19. | Blackrock Russell 2000 Alpha Tilts Fd A | 2 years ago | 228015 |
| 20. | Multi-Manager Small Cap Eq Strat Inst | 2 years ago | 219719 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Deep Track Capital, LP | 2 years ago | 18400000 |
| 2. | Vanguard Group Inc | 2 years ago | 12049138 |
| 3. | Acadian Asset Management LLC | 2 years ago | 7569063 |
| 4. | PRIMECAP Management Company | 2 years ago | 6966647 |
| 5. | BlackRock Inc | 2 years ago | 6104217 |
| 6. | Monaco Asset Management | 2 years ago | 5831565 |
| 7. | Renaissance Technologies Corp | 2 years ago | 5325475 |
| 8. | Stonepine Capital Management Llc | 2 years ago | 3480409 |
| 9. | Millennium Management LLC | 2 years ago | 2984545 |
| 10. | D. E. Shaw & Co LP | 2 years ago | 2548990 |
| 11. | Nantahala Capital Management, LLC | 2 years ago | 2475954 |
| 12. | Two Sigma Advisers, LLC | 2 years ago | 2240342 |
| 13. | Two Sigma Investments LLC | 2 years ago | 2081940 |
| 14. | Shay Capital LLC | 2 years ago | 2079674 |
| 15. | Geode Capital Management, LLC | 2 years ago | 2039614 |
| 16. | GSA Capital Partners LLP | 2 years ago | 1989905 |
| 17. | Jacobs Levy Equity Management, Inc. | 2 years ago | 1911186 |
| 18. | Goldman Sachs Group Inc | 2 years ago | 1727738 |
| 19. | Assenagon Asset Management SA | 2 years ago | 1687300 |
| 20. | Marshall Wace Asset Management Ltd | 2 years ago | 1471237 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...